09:25 AM EDT, 07/17/2024 (MT Newswires) -- ICL Group ( ICL ) and Evogene ( EVGN ) subsidiary Lavie Bio said Wednesday that their collaboration using artificial intelligence has helped identify more than a dozen novel microbial candidates with commercial viability.

The collaboration is seeking candidates that could be used as bio-stimulants for crops grown under extreme weather conditions, including drought, the companies said.

The progress will allow for field trials in both the US and Brazil during the second half of 2024 and results are expected by year-end, the companies said.

Lavie Bio and ICL expect to begin the regulatory process in 2026.

Price: 4.4600, Change: -0.07, Percent Change: -1.55